Talarico Ernest III 4

Accession 0001126234-19-000109

CIK 0001126234other

View on SEC.gov Company Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 6:41 PM ET

Size

53.2 KB

Accession

0001126234-19-000109

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Talarico Ernest III

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−23,809→ 0 total
Exercise: $3.07From: 2011-03-03Exp: 2020-03-02→ Common Stock (23,809 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+1,190→ 1,190 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (1,190 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,968→ 3,968 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,968 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−6,349→ 0 total
Exercise: $44.60Exp: 2025-04-29→ Common Stock (6,349 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−17,774→ 0 total
Exercise: $10.78Exp: 2026-08-08→ Common Stock (17,774 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−4,782→ 0 total
Exercise: $10.78Exp: 2026-08-08→ Common Stock (4,782 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−27,777→ 0 total
Exercise: $5.33Exp: 2028-05-22→ Common Stock (27,777 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−11,904→ 0 total
Exercise: $10.02From: 2012-01-01Exp: 2020-12-08→ Common Stock (11,904 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+11,905→ 11,905 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (11,905 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,952→ 5,952 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,952 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+5,220→ 5,220 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (5,220 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+1,588→ 1,588 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (1,588 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,391→ 2,391 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,391 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−13,309→ 0 total
Exercise: $17.42Exp: 2027-05-11→ Common Stock (13,309 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,437→ 4,437 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,437 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+11,905→ 11,905 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (11,905 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−23,809→ 0 total
Exercise: $3.07From: 2010-03-03Exp: 2020-03-02→ Common Stock (23,809 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−2,380→ 0 total
Exercise: $10.02From: 2011-12-09Exp: 2020-12-08→ Common Stock (2,380 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−11,902→ 0 total
Exercise: $13.30Exp: 2022-11-01→ Common Stock (11,902 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,000→ 4,000 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−15,659→ 0 total
Exercise: $21.23Exp: 2024-04-30→ Common Stock (15,659 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−12,000→ 0 total
Exercise: $14.71Exp: 2023-05-08→ Common Stock (12,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+8,887→ 8,887 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (8,887 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+13,889→ 13,889 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (13,889 underlying)

Footnotes (6)

[F1]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F2]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F3]The option provided that 50% of the option vested on November 2, 2013 and the remaining 50% of such option vested in equal monthly installments over the next 12 months, provided (i) that the option shall vest in full on the date of the Annual Meeting held two years after the date of grant and (ii) that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
[F4]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every three cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F5]The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.
[F6]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every four cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.

Documents

1 file

4
wf-form4_156478564691015.xmlPrimary
FORM 4

Issuer

NEWLINK GENETICS CORP

CIK 0001126234

→

Entity typeother

Related Parties

filerCIK 0001512132

Filing Metadata

Form type: 4
Filed: Aug 1, 8:00 PM ET
Accepted: Aug 2, 6:41 PM ET
Size: 53.2 KB

View on SEC.gov